Skip to main content
SpringerLink
Log in

Treatment of the haemophilias

  • Chapter
Supportive therapy in haematology

  • 93 Accesses

Abstract

Prompt treatment, or prophylaxis, with blood products allows the majority of patients with haemophilia A and B the prospect of leading relatively normal lives. Along with von Willebrand’s disease (vWD), these disorders are numerically and clinically the most important congenital bleeding conditions. The prevelence of haemophilia A is approximately five per hundred thousand of population whereas vWD is probably about half this and haemophilia B (Christmas disease) one fifth; other congenital coagulation deficiencies are rare. Although clinically severe congenital platelet disorders are uncommon, it is becoming increasingly acknowledged that minor abnormalities of platelet function may be relatively common and on occasion clinically important.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bloom AL: Inherited Disorders of Blood Coagulation. In: Haemostasis and Thrombosis, Bloom AL, Thomas DP, (eds). Churchill Livingston, 1981; 321–70.

    Google Scholar 

  2. Arnold WD, Hilgartner MW: Haemophilic arthropathy. J Bone Joint Surg, 1977; 59: 287–305.

    PubMed  CAS  Google Scholar 

  3. Rizza CR: Management of patients with inherited blood coagulation defects. In: Haemostasis and Thrombosis, Bloom AL, Thomas DP (eds). Churchill Livingston, 1981; 371–94.

    Google Scholar 

  4. Aronstram A, Choudhury DP, Wassef M, Turk PM, McLellan DS: Double blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. Lancet, 1980; is 169–71.

    Google Scholar 

  5. Allain JP: Dose requirement for replacement therapy in haemophilia A. Thrombosis and Haemostasis, 1979; 42: 825–31.

    PubMed  CAS  Google Scholar 

  6. Aronstam A, Wassef M, Hamad Z: Low doses of factor VIII for selected ankle bleeds in severe haemophilia A. Br Med J, 1982; 284: 790.

    Article  CAS  Google Scholar 

  7. Small M, Rose PE, MacMillan N, Belch J, Rolfe EB, Forbes CD, Stuart J: Haemophilia and the kidney assessment after 11 year follow-up. Br Med J, 1982; 285: 1609–11.

    Article  CAS  Google Scholar 

  8. Jones P, Fearns M, Forbes C, Stuart J: Haemophilia A home therapy in the United Kingdom 1975–7. Br Med J, 1978; is 1447–50.

    Google Scholar 

  9. Aronstam A, McLellan DS, Turk P: Transfusion requirements of adolescents with severe haemophilia A. J Clin Path, 1979; 32: 927–30.

    Article  PubMed  CAS  Google Scholar 

  10. Duthie RB, Matthews JM, Rizza CR, Steel WM: The Management of Musculoskeletal Problems in the Haemophiliacs. Blackwell Scientific Publications 1972.

    Google Scholar 

  11. Walsh PN, Rizza CR, Mathews JM, Eipe J, Kernoff PBA, Coles MD, Bloom AL, Kaufman BM, Beck P, Hanan CM, Biggs R: Epsilon-amino caproic acid therapy for dental extraction in haemophilia and Christmas disease: a double blind trial. Br J Haematol, 1971; 20: 463–75.

    Article  PubMed  CAS  Google Scholar 

  12. Pool JG, Shannon AE: Production of high potency anti-haemophilic factor concentrate prepared from cryoglobulin precipitate. Nature, 1971; 203: 312.

    Article  Google Scholar 

  13. Mason EC: Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII. Lancet, 1981; ii: 15–17.

    Google Scholar 

  14. Smit Sibinga CTh, Welbergen H, Das PC, Griffin B: High yield method of production of freeze-dried purified factor VIII by blood banks. Lancet, 1981; ii: 61–62.

    Google Scholar 

  15. Rickard KA, Batey RG, Dovity P, Johnston S, Campbell J, Hodgson J: Hepatitis and Haemophilia Therapy in Australie. Lancet, 1982; ii: 146–40.

    Google Scholar 

  16. Stirling ML, Murray J, MacKay P, Black SH, Peutherer JF, Ludlam CA: Incidence of infection with hepatitis B virus in 56 patients with haemophilia A, 1971–1979. J Clin Path, 1983; 36: 577–80

    Article  PubMed  CAS  Google Scholar 

  17. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A: Deamino-8-D-argenine vasopressin; a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet, 1977; is 869.

    Google Scholar 

  18. Bamber M, Murray A, Arborgh BA, Scheuer PJ, Kernoff PB, Thomas HC, Sherlock S: Short incubation non A non B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut, 1981; 22: 854–9.

    Article  PubMed  CAS  Google Scholar 

  19. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A: Hepatitis B vaccine. Demonstration of efficacy in a control led clinical trial in a high-risk population in the United States. N Eng J Med, 1980; 303: 833–941.

    Article  CAS  Google Scholar 

  20. Preston FE, Triger DR, Underwood JCE, Bardhan G, Mitchell VE, Stewart RM, Blackburn EK: Percutaneous liver biopsy and chronic liver disease in haemophiliacs. Lancet, 1978; ii: 592–94.

    Google Scholar 

  21. Spero JA, Lewis JH, Van Thiel DH, Hasiba U, Rabin BS: Asymptomatic structural liver disease in haemophilia. N Engl J Med, 1978; 298: 1373–78.

    Article  PubMed  CAS  Google Scholar 

  22. Macek C: Acquired immunodeficiency syndrome cause still elusive. JAMA, 1982; 248: 1423–31.

    Article  PubMed  CAS  Google Scholar 

  23. Ragni MV, Lewis JH, Spero JA, Bontempo FA: Acquired immunodeficiency-like syndrome in two haemophiliacs. Lancet, 1983; is 213–14.

    Google Scholar 

  24. Menitove JE, Aster RH, Casper JT, Lauer SJ, Gottschall JL, Williams JE, Gill JC, Wheeler DV, Piaskowski V, Kirchner P, Montgomery RR: T-Lymphocyte subpopulations in patients with classic haemophilia treated with cryoprecipitate and lyophilised concentrates. N Eng J Med, 1982; 308: 79–83.

    Google Scholar 

  25. Lederman MM, Ratnoff OD, Scillian JJ, Jones PK, Schacter B: Impaired cell-mediated immunity in patients with classic haemophilia. N Engl J Med, 1982; 308: 79–83.

    Article  Google Scholar 

  26. Allain JP, Gaillandre A, Lee H: Immunochemical characterization of antibodies to factor VIII in hemophilic and nonhemophilic patients. J Lab Clin Med, 1981; 97: 791–800.

    PubMed  CAS  Google Scholar 

  27. Green D, Lechner K: A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thrombosis and Haemostasis, 1981; 45: 200–208.

    PubMed  CAS  Google Scholar 

  28. Wensley RT, Stevens RF, Burn AM, Delamore IW: Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors. Br Med J, 1980; 281: 138–9.

    Article  Google Scholar 

  29. Slocombe GW, Newland AC, Colvin MP, Colvin BT: The Role of Intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. Br J Haematol, 1981; 47: 577–85.

    Article  PubMed  CAS  Google Scholar 

  30. Kernoff PBA, Thomas ND, Lilley PA, Tuddenham EGD: Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate. Br J Haematol, 1981; 49: 131.

    Google Scholar 

  31. Sjamsoedin LJM, Heijnen L, Nauser-Bunschoten EP, Van Geijiswijk JL, Van Houwelingen H, Van Asten P, Sixma JJ: The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII. N Eng J Med, 1981; 305: 717–21.

    Article  CAS  Google Scholar 

  32. Abildgaard CF, Penner JA, Watson-Williams EJ: Antiinhibitor coagulant complex (autoplex) for treatment of factor VIII inhibitors in haemophilia. Blood, 1980; 56: 97884.

    Google Scholar 

  33. Hanna WT, Madigan RR, Miles MA, Lange RD: Activated factor IX complex in treatment of surgical cases of haemophilia A with inhibitors. Thrombosis Haemostasis, 1981; 46: 638–41.

    CAS  Google Scholar 

  34. Bloom AL: Factor VIII inhibitors revisited. Br J Haematol, 1981; 49: 319–24.

    Article  PubMed  CAS  Google Scholar 

  35. Barrowcliffe TW, Kemball-Cook G, Gray E: Factor VIII Inhibitor bypassing activity: A suggested mechanism of action. Thrombosis Res, 1981; 21: 181–86.

    Article  CAS  Google Scholar 

  36. Lusher JM, Shapiro SS, Palascak JE, Vijaya Rao A, Levine PH, Blatt PM, Haemophilia Study Group: Efficacy of pro-thrombin complex concentrates in haemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med, 1980; 303: 421–25.

    Article  PubMed  CAS  Google Scholar 

  37. Rodeghiero F, Castronovo S, Dini E: Disseminated intravascular coagulation after infusion of FEIBA (Factor VIII Inhibitor Bypassing Activity) in a patient with acquired haemophilia. Thrombosis Haemostasis, 1982; 48: 339–40.

    CAS  Google Scholar 

  38. Schimpf KL, Zeltsch CH, Zeltsch P: Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with haemophilia A. Lancet, 1982; ii: 1043.

    Google Scholar 

  39. Abildgaard CF: Hazards of Prothrombin-complex concentrates in treatment of haemophilia. N Engl J Med, 1981; 304: 670.

    PubMed  CAS  Google Scholar 

  40. Nilsson IM, Hedner U: Characteristics of various factor VIII concentrates used in treatment of haemophilia A. Br J Haematol, 1978; 37: 543.

    Article  Google Scholar 

  41. Bloom AL, Peake IR, Furlong RA, Davies BL: High potency factor VIII concentrate, more effective than cryoprecipitate in a patient with von Willebrand’s disease and inhibitor. Thrombosis Res, 1979; 16: 847.

    Article  CAS  Google Scholar 

  42. Jones P: Organisation of a haemophilia service. Haemostasis and Thrombosis, Bloom AL, Thomas DP (eds). Churchill Livingstone 1981; 389–93.

    Google Scholar 

  43. Temperley I: National Resources and the Use of factor VIII. In: Bloodtransfusion and problems of bleeding, Smit Sibinga CTh, Das PC, Vanloghem JS (eds). Martinus Nijhoff, 1982; 243–47.

    Google Scholar 

  44. Rizza CR, Spooner RJD: Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976–80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J, 1983; 236: 929–33.

    Article  Google Scholar 

Download references

Authors
  1. C. A. Ludlam
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank, Groningen-Drenthe, The Netherlands

    P. C. Das  & C. Th. Smit Sibinga  & 

  2. Dept. of Haematology, University Hospital, Groningen, The Netherlands

    M. R. Halie

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers. Boston/Dordrecht/Lancaster

About this chapter

Cite this chapter

Ludlam, C.A. (1985). Treatment of the haemophilias. In: Das, P.C., Sibinga, C.T.S., Halie, M.R. (eds) Supportive therapy in haematology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2577-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2577-2_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9617-1

  • Online ISBN: 978-1-4613-2577-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation